Figures at a glance

Figure 1

Figure 2

Figure 3

FIGURE 1

Figure1: Tumour markers including CEA, NSE and Cyfra21-1 continued to decline from first to third cycle treatment.

FIGURE 2

Figure 2a+b. Computed tomography (CT) imaging of primary lesion at different times: (A) before treatment; (B) after two cycles of neoadjuvant immunochemotherapy; (C) after another cycle of neoadjuvant immunochemotherapy; Figure 2c+d. CT imaging of contralateral hilar and mediastinal lymph nodes at different times

FIGURE 3

Figure 3A-D. A fluorodeoxyglucose positron emission tomography (FDG‐PET) scan demonstrated that the local residual tumor with slightly high FDG metabolism, the left hilar and mediastinal lymph node enlargement with high FDG metabolism.